ZA991765B - Pharmaceutical compositions containing in combination a selective V1a arginine vasopressin receptor antagonist and a selective V2 arginine vasopressin receptor antagonist. - Google Patents

Pharmaceutical compositions containing in combination a selective V1a arginine vasopressin receptor antagonist and a selective V2 arginine vasopressin receptor antagonist.

Info

Publication number
ZA991765B
ZA991765B ZA9901765A ZA991765A ZA991765B ZA 991765 B ZA991765 B ZA 991765B ZA 9901765 A ZA9901765 A ZA 9901765A ZA 991765 A ZA991765 A ZA 991765A ZA 991765 B ZA991765 B ZA 991765B
Authority
ZA
South Africa
Prior art keywords
selective
receptor antagonist
vasopressin receptor
arginine vasopressin
combination
Prior art date
Application number
ZA9901765A
Other languages
English (en)
Inventor
Colette Lacour
Dino Nisato
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA991765B publication Critical patent/ZA991765B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ZA9901765A 1998-03-06 1999-03-04 Pharmaceutical compositions containing in combination a selective V1a arginine vasopressin receptor antagonist and a selective V2 arginine vasopressin receptor antagonist. ZA991765B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802874A FR2775598A1 (fr) 1998-03-06 1998-03-06 Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine

Publications (1)

Publication Number Publication Date
ZA991765B true ZA991765B (en) 1999-09-06

Family

ID=9523839

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901765A ZA991765B (en) 1998-03-06 1999-03-04 Pharmaceutical compositions containing in combination a selective V1a arginine vasopressin receptor antagonist and a selective V2 arginine vasopressin receptor antagonist.

Country Status (10)

Country Link
US (1) US6627649B1 (xx)
EP (1) EP1063996A1 (xx)
JP (1) JP2002505289A (xx)
AR (1) AR016984A1 (xx)
AU (1) AU2629299A (xx)
CO (1) CO5070635A1 (xx)
FR (1) FR2775598A1 (xx)
GT (1) GT199900027A (xx)
WO (1) WO1999044613A1 (xx)
ZA (1) ZA991765B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US8445461B2 (en) 2007-01-10 2013-05-21 Setsuko Takeda Pharmaceutical composition for meniere's disease
EP2352499A1 (en) * 2008-10-10 2011-08-10 Janssen Pharmaceutica, N.V. Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
US20200337590A1 (en) 2018-01-16 2020-10-29 Bayer Aktiengesellschaft Assistance in the treatment of cardiac insufficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
US5338755A (en) 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
AR016984A1 (es) 2001-08-01
CO5070635A1 (es) 2001-08-28
JP2002505289A (ja) 2002-02-19
EP1063996A1 (fr) 2001-01-03
GT199900027A (es) 2000-08-19
WO1999044613A1 (fr) 1999-09-10
FR2775598A1 (fr) 1999-09-10
US6627649B1 (en) 2003-09-30
AU2629299A (en) 1999-09-20

Similar Documents

Publication Publication Date Title
HUP0100266A3 (en) 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing the compounds and their preparations
HUP0203556A3 (en) Pharmaceutical compositions containing oxcarbazepine and their use
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HUP0303081A3 (en) Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
EP0975336A4 (en) RAPID RESOLVABLE STABLE PHARMACEUTICAL FORM
HUP0103796A3 (en) Neuropeptide y5 receptor antagonists and medicaments containing them
HUP0102658A3 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
PL348375A1 (en) Pyrrolidine derivatives-ccr-3 receptor antagonists
GB0011095D0 (en) astrin and cholecystokinin receptor ligands (III)
EP1015351A4 (en) CHAMBER WITH DRUG DELIVERY
HUP0103542A3 (en) 4,4-biarylpiperidine derivatives with opioid receptor activity and pharmaceutical compositions containing them
IL137990A0 (en) A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
IL139865A0 (en) A liver selective glucocorticoid antagonist and pharmaceutical compositions containing the same
HUP0100607A3 (en) Thrombin receptor antagonists and pharmaceutical compositions containing them
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP0002929A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
ZA991765B (en) Pharmaceutical compositions containing in combination a selective V1a arginine vasopressin receptor antagonist and a selective V2 arginine vasopressin receptor antagonist.
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
HUP0500079A3 (en) Chemokine receptor antagonists, their use and pharmaceutical compositions containing them
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
HUP0002714A3 (en) Betha-amino and betha-azidocarboxylic acid derivatives, and pharmaceutical compositions containing them as endothelin receptor antagonists
HUP0003548A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
IL141899A0 (en) Pharmaceutical compositions comprising a chemokine receptor antagonist and a cyclosporin
AU3425999A (en) Pharmaceutical compositions containing in combination an arginine-vasopressin v 1a antagonist and an angiotensin II at 1 receptor antagonist
GB0026327D0 (en) Thrombin receptor antagonists